Efficacy and mechanism of bifaer (prostaglandin E1)in the treatment of male patients with erectile dysfunction

Abstract

Abstract: Prostaglandin E1 cream preparation (bifaer) can relax arteria smooth muscle and adjust the release of NA in corpus cavernosum in penis.Multicenter clinical trials have conformed that bifaer shows usefulness and safety in treatment of male patients with erectile dysfunction through.

Key words: pharmacology, review, prostaglandin E¹, bifaer cream preparation, erectile dysfunction, clinical trials

CLC Number:

R972.4
R698

MU Ye-Jun, LU Min-Qi. Efficacy and mechanism of bifaer (prostaglandin E1)in the treatment of male patients with erectile dysfunction[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2003, 8(3): 255-260.

References

[1] Euler US.Uber die spezifische blutdrucksenkende substanzdes menschlichen prosata-und samenblasensekretes[J].Klin Woschr, 1935;14:1182
[2] Bergstrom S, Ryhage R, Samuelesson B, et al.Prostaglandins and related factors.The structure of prostaglandin E1, F1A and F1B[J].J Biol Chem, 1963;238:3555-64
[3] Bergstrom S, Sjovall J.The isolation of prostaglandin E from sheep prostate glands[J].Acta Chem Scand, 1960;14:1701-5
[4] Kirtland S.Prostaglandin E1:A Review[J].Prostaglandins Leukot rienes Essent Fatty Acids, 1988;32:165-74
[5] Wespes E, Delcour C, Struyven J, et al.The erectile angle: objective criterio to evaluate the papaverine test in impotence[J].J Urol, 1987;138:1171
[6] Carlson LA, Eriksson I.Femoral-artery infusion of prostaglandin E1 in severe peripheral vascular disease[J].Lancet, 1973;1: 155
[7] Porst H.The rationale for prostaglandin E1 in erectile failure:a survey of worldwide experience[J].J Urol, 1996;155:802-15
[8] Roy AC, Adaikan PG, Sen DK, et al.Prostaglandin 15- hydroxydehydrogenase activity in human penile corpora cavemosa and its significance in prostaglandin-mediated penile erection[J].J Urol, 1989;64:180
[9] Van Ahlen H, Peskar B, Sticht G, et al.Pharmacokinetics of vasoactive substances administered into the human corpus cavernosum[J].J Urol, 1994;151:1227-30
[10] Creutzig A, Caspary L.Prostanoids in therapy of peripheral arterial occlusive disease[J].Therapie, 1991;46:241-5
[11] Herdrich H, Breddin HK, Rudofsky G.Cardiopulmonary effects and safety of prostaglangin E1:A Review[J].Int J Angiol, 1994;3:160-8
[12] Cox J, Andreadis N, Bone R.Pulmonary extraction and pharmacokinetics of prostaglandin E1 during continuous intravenous infusion in patients with adult respiratory distress syndrome[J]. Am Rev Respir Dis, 1988;137:5-12
[13] Cawello W, Schweer H, Dietrich B.Pharmacokinetics of prostaglandin E1 and its main metobolites after intracavernous injection and short-term infusion of prostaglandin E1 in patients with erectile dysfunction[J].J Urol, 1997;158:1403-7
[14] Leas AP, Bryson HM, Balfour JA.Intracavernous alprostadil. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in erectile dysfunction[J].Drugs Aging, 1996;8:56-74
[15] Linet O, Neff L.Intracavernous prostaglandin E1 in erectile dysfunction[J].Clin Investig, 1994;72:139-49
[16] Linet O, Ogrinc F.Efficacy and safety of intracavernosal alprostadil in men with erectile dysfunction[J].N Engl J Med, 1996;334:873-7
[17] Pharmacia &Upjohn.Caverject (Brand of Alprostadil for Injection)[J].Caverject prescribing information, 1998:9-10
[18] Paoletti R.Biochemistry and pharmacology of prostaglandin E1: introductory remarks[A].In:Prostaglandin E1 in Atherosclerosis[M].Springer-Verlag, 1986:3-7
[19] Kawasakin A.Effect of prostaglandin E1-cyclodextrin clathrate compound (PGE1-alpha CD) on the experimental model of acute arterial obstruction.Relating to its vasodilator and antiplatelet aggregation action[J].Oyo Yakuri, 1971;17:1043
[20] Lumley P.Comparison of the potencies of some prostaglandins as vasodilators in three vascular beds of the anaesthetised dog[J].Eur J Pharmacol, 1982;81:421
[21] Schror K, Smith EF.Ⅲ:Dictionary of Prostaglandins[M]. New York:Medikon-Verlag, 1990:100
[22] Sinzinger H.Inhibition of mitotic and proliferative activity of smooth muscle cells by prostaglandin E1[A].In:Sinzinger H, Rogatti W, eds.prostaglandin E1 in Atherosclerosis[M].New York:Spring-Verlag, 1986:39-48
[23] Rexroth W.Effekte von PGE1 aufhamodynamik und extremitatenstoffwechsel bei gesunden und patienten mit arterieller ver-schlusskrankheit stadium Ⅲ[J].IV VASA, 1985;14:220
[24] Blume J, Ruhlmann KU, Kiesewetter H.Clinical efficacy of intraarterial PGE1-infusion in intermittent claudication[A].In: Sinzinger H, Rogatti W, eds.prostaglandin E1 in Atherosclerosis[M].New York:Spring-Verlag, 1986:75-80
[25] Bruch HP, HorlM, Herold A.Prostaglandin E1 in arterial occlusive disease in stages Ⅲ and Ⅳ according to Fontaine[A]. In:Sinzinger H, Rogatti W, eds.Prostaglandin E1 Athrosclerosis[M].New York:Spring-Verlag, 1986:81-91
[26] Hach W, Zanke BW, Sauerwein G, et al.Treatment of stage Ⅱ b peripheral arterial occlusive disease with short-term intraarterial infusions of prostaglandin E1[A].In:Sinzinger H, Rogatti W, eds.Prostaglandin E1 in Atherosclerosis[M].New York:Spring-Verlag, 1986:66-74
[27] Herdrich H.Long-term intravenous infusion of PGE1 in peripheral arterial lood flow disorders:results of an open screeing study with patients in Fontaine' s stages Ⅲ and Ⅳ[A].In: Sinzinger H, Rogatti W, eds.Prostaglandin E1 in Atherosclerosis[M].New Youk:Spring-Verlag, 1986:92-8
[28] Moltz H.Eseries prostaglandins and arginine vasoprssin in the modulation of male sexual behavior[J].Neurosci Biobehav Rev, 1990;14:109
[29] Molderings GJ, van Ahlen H, Gothert M.Moldulation of noradrenaline release in human corpus cavernosum by presynaptic prostaglandin receptors[J].Int J Impot Res, 1992;4:19
[30] SaenZ de Tejada I, Moreland RB.Physiology of erection, pathophysiology of impotence and implications of PGE1 in the control of collagen synthesis in the corpus cavernosum[A].In: Goldstein I, Lue TF, eds.The role of alprostadil in the diagnosis and treatment of erectile dysfunction[M].Princetion:Excerpta Mdica Inc, 1993;卷:3-6
[31] Aversa A, Isidori.Penile pharmacotesting in diagnosing male erectile dysfunction:evidence for lack of accuracy and specificity[J].Int J Androl, 2002;52:6-10
[32] Belcaro G, Cesarone MR, Nicolaides AN, et al.Microcirculatory strdies in erectile disorders[J].Curr Med Res Opin, 2000;16:72-5
[33] Chandeck Montesa K.Prospective study of the effectiveness and side effects of intracavernous prostaglandin E1 Versus papaverine or papaverine phentolamine in the diagnosis and treatment of erection dysfunction[J].Actas Urol Esp, 1992;16:208-16
[34] Choi HK, Adimoelija A, Kim SC, et al.A dose-response study of alprostadil sterile powder (S.Po.)(Caverject)for the treatment of erectile dysfunction in Korean and Indonesian men[J].Int J Impot Res, 1997;9:45-51
[35] Isidori A, Aversa A, Fabbri A.Erectile dysfunction[J].Recenti Prog Med Jul-Aug, 1999;90:396-402
[36] Metro MJ, Broderick GA.Diabetes and vascular impotence: does insulin dependence increase the relative severity[J] ? Int J Impot Res, 1999;11:87-9
[37] Becher E, Borghi M, Momesso A, et al.Penile hemodynamic findings with a new topical formulation of alprostadil[J].J Urol, 2001;159:239
[38] Zhao D.Treatment of Erectile Dysfunction with PGE1 Cream[J].Nation J Andrology, 2000;4:238-40
[39] Guo YL, Zhu JC.Efficacy and safety of prostaglandin E1 (PGE1)cream in the treatment of erectile dysfunction[C].The 9th world meeting on Impotence Research in Perth, Australia, 2000:26-9